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Abstract. Motion and uncertainty in radiotherapy is traditionally handled via31
margins. The clinical target volume (CTV) is expanded to a larger planning target32
volume (PTV), which is irradiated to the prescribed dose. However, the PTV33
concept has several limitations, especially in proton therapy. Therefore, robust and34
probabilistic optimization methods have been developed that directly incorporate35
motion and uncertainty into treatment plan optimization for intensity modulated36
radiotherapy (IMRT) and intensity modulated proton therapy (IMPT). Thereby, the37
explicit definition of a PTV becomes obsolete and treatment plan optimization is38
directly based on the CTV. Initial work focused on random and systematic setup errors39
in IMRT. Later, inter-fraction prostate motion and intra-fraction lung motion became40
a research focus. Over the past 10 years, IMPT has emerged as a new application for41
robust planning methods. In proton therapy, range or setup errors may lead to dose42
degradation and misalignment of dose contributions from different beams a problem43
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that cannot generally be addressed by margins. Therefore, IMPT has led to the first44
implementations of robust planning methods in commercial planning systems, making45
these methods available for clinical use. This paper first summarizes the limitations46
of the PTV concept. Subsequently, robust optimization methods are introduced and47
their applications in IMRT and IMPT planning are reviewed.48
1. Introduction49
Radiotherapy aims at delivering curative doses of radiation to tumors while minimiz-50
ing the risk of side effects in healthy tissues. In that regard, radiotherapy treatment51
planning and delivery faces many uncertainties. Target volume definition, the first step52
in the treatment planning chain, is associated with substantial uncertainty. Definition53
of the gross tumor volume (GTV) has limitation not only due to finite resolution of54
medical images, but also because current imaging modalities only visualize surrogates55
for the presence of tumor and not tumor cells per se. Delineation of the clinical target56
volume (CTV) faces even larger uncertainty because currently available imaging modal-57
ities cannot visualize microscopic disease. Subsequently, there is uncertainty in dose58
prescription and normal tissue tolerances. For an individual patient, the dose that is59
needed to control the tumor is uncertain. Current research aims to predict an individual60
patient’s response to radiation based on biomarkers in order to personalize prescription61
doses or normal tissue constraints, however, such approaches are not yet widely estab-62
lished. In summary, the ideal dose distribution that radiotherapy planning should be63
aiming at is uncertain in the first place.64
65
In addition, there is uncertainty in the dose distribution delivered to the patient, i.e.66
potential discrepancies between the dose distribution shown in the treatment planning67
system and the actually delivered dose. The most prominent reasons for that are setup68
errors, changes of the patient geometry over the course of treatment, and uncertainty in69
dose calculation. Changes in the patient geometry include, for example, inter-fraction70
motion of the prostate as well as intra-fraction motion in the lung or liver due to respira-71
tion. Dose calculation errors arise in part from the use of approximate pencil beam dose72
calculation algorithms, which are used for computational efficiency at the cost of lower73
accuracy compared to methods that are directly based on modeling the physical inter-74
actions of radiation in tissue. In proton therapy, range uncertainty can be considered a75
specific form of dose calculation uncertainty. The Hounsfield numbers of the planning76
CT are in unideal input for proton dose calculation algorithms due to uncertainty in the77
conversion of Hounsfield numbers to proton stopping power. In addition, pencil beam78
dose calculation algorithms may inaccurately model the degradation of the Bragg peak79
in heterogeneous media.80
81
This paper will deal with uncertainties in the delivered dose distribution. Treatment82
planning should aim at creating plans that are robust against uncertainty. Robustness of83
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a treatment plan refers to two properties: first, the CTV should receive the prescribed84
dose despite errors that may occur; and second, normal tissue constraints should be85
satisfied despite potential errors in planning or delivery. Setup and motion-related un-86
certainty is traditionally handled via safety margins, i.e. by expanding the irradiated87
region around the tumor. In IMRT planning, margins are added around the CTV in88
order to obtain the planning target volume (PTV). Treatment planning aims to have the89
PTV receive the prescription dose. It is then assumed that, as long as the CTV moves90
only within the boundaries of the PTV, the prescribed dose is delivered to the CTV.91
The required margin depends on the magnitude of the error and general margin recipes92
have been developed [1, 2, 3]. Typically, the priority in treatment planning is to make93
sure that the CTV receives the prescribed dose despite uncertainty. In specific cases,94
especially when the OAR is serial, respecting maximum dose constraints to normal tis-95
sues is prioritized over CTV coverage. An example is stereotactic body radiotherapy96
for spinal metastases, where sparing of the spinal cord is more important than target97
coverage. In this case, the spinal cord is expanded by a margin to create a planning risk98
volume (PRV). Treatment planning creates a plan that does not exceed the maximum99
dose to the spinal cord in all of the PRV.100
101
The PTV concept has several limitations. To address these limitations, robust102
planning methods have been developed that directly incorporate uncertainty into103
treatment plan optimization for IMRT and IMPT. Thereby, the definition of a PTV104
or PRV becomes obsolete and treatment planning is based on the CTV directly. In105
September 2015, the authors and other researchers met at Massachusetts General106
Hospital in Boston to discuss the state-of-the-art in robust treatment planning. The107
goals of this joint review are:108
1. We first summarize the limitations of the PTV concept to provide the motivation109
for robust planning (section 2).110
2. We formally introduce the main concepts used in robust planning, namely stochastic111
programming and minimax optimization (section 3).112
3. We review the main applications of robust planning. In particular, random and113
systematic setup errors and inter-fraction organ motion in IMRT (section 4),114
systematic range and setup errors in IMPT (section 5), and respiratory motion115
(section 6).116
We provide a comprehensive review of robust planning approaches found in the117
literature. Different approaches are formulated using a unified notation. Thereby, their118
relation and differences can be understood. This paper serves as both a review of the119
literature as well as a tutorial style introduction to the concepts and main applications120
of robust optimization in radiotherapy.121
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2. Limitations of the PTV concept122
While margins and PTVs are used throughout in clinical practice, there are several123
limitations of the PTV concept, which motivate the development of robust planning. In124
some situations, the PTV concept has fundamental limitations and does not guarantee125
target coverage irrespective of the size of the margin; in other situations a large enough126
PTV may ensure coverage of the CTV, but may not yield the optimal tradeoff between127
target coverage and OAR sparing.128
1. Breakdown of the static dose cloud approximation: The PTV concept129
as typically applied in IMRT planning relies on the so-called static dose cloud130
approximation, i.e. the assumption that the dose distribution in treatment room131
coordinates is unaffected by changes in the patient’s anatomy. That is, it is assumed132
that the CTV receives the prescribed dose as long as it stays within the PTV. This133
fundamental assumption is not generally fulfilled and is violated, in particular, in134
IMPT (section 5).135
2. Build-in margins for non-conformal plans: Whether or not the CTV receives136
the prescribed dose depends on the dose distribution rather than geometric margin137
concepts. In reality, dose distributions are neither perfectly conformal to the PTV138
nor equally conformal on all sides of the CTV. Non-conformity results in an inherent139
dosimetric margin [4]. In those regions where the prescription isodose line extends140
beyond the CTV anyway, less or no margin needs to be added to account for141
setup uncertainty. In addition to conformity, the required margin also depends on142
the steepness of the dose fall-off near the target. A naturally shallow fall-off may143
require a smaller margin than a steep fall-off. The optimal margin may therefore144
be unisotropic.145
3. Optimally balancing tumor coverage and normal tissue sparing: TCP and146
NTCP models are increasingly used for treatment plan evaluation, and may play147
a larger role in treatment plan optimization in the future. However, using a PTV148
dose distribution as input to a TCP model has conceptual flaws. Furthermore,149
underdosing the edge of the PTV may give low predicted TCP values, even though150
the underdosage may only occur for specific setup errors in the corresponding151
direction, while in most cases the CTV is covered. Optimally balancing TCP and152
NTCP requires proper handling of geometric uncertainties.153
4. Dose painting: In the context of dose painting based on functional imaging, the154
use of margins for different prescription dose levels becomes cumbersome.155
5. Edge enhancement or horns: The PTV approach, as well as the internal target156
volume (ITV) approach for respiratory motion aim to deliver the prescribed dose to157
all regions were the tumor may be. Thereby, the same dose is delivered to regions158
that are always occupied by tumor and regions where the tumor is rarely. In159
the presence of motion, and when the total tumor dose is achieved by accumulating160
dose contributions from multiple geometric instances, the approach is suboptimal in161
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terms of normal tissue sparing. The normal tissue dose can be reduced by delivering162
less dose to regions where the tumor is rarely. In order to not compromise target163
coverage, this has to be compensated for by delivering higher doses to regions mostly164
occupied by the tumor. Such dose distributions, which show dose hot spots inside165
or at the edge of the target when delivered to a static geometry, have been referred166
to as edge enhanced or horns (sections 4.2, 6).167
3. Robust planning concepts168
3.1. Conventional treatment plan optimization169
IMRT and IMPT treatment planning is generally formulated as a mathematical170
optimization problem. Treatment plan quality is mathematically defined via an171
objective function f . A good treatment plan corresponds to a low objective function172
value. The best treatment plan is found by minimizing the objective function with173
respect to beamlet intensities using mathematical optimization algorithms. The174
objective function f(d; q) is a function of the dose distribution d, and additionally175
depends on parameters q such as prescription doses and tolerances for normal tissues.176
Formally, the fluence map optimization problem for IMRT and IMPT can be written as177
minimize
x
f(d; q) (1)178
subject to d = Dx (2)179
x ≥ 0 (3)180
The dose distribution d = Dx is a linear function of the incident fluence x. D denotes181
the dose-influence matrix whose elements Dij store the dose contribution of beamlet j182
to voxel i for unit fluence.183
3.2. Types of uncertainty184
In this setting, three types of uncertainty can be distinguished.185
1. Uncertainty in the dose-influence matrix D. This means that the same treatment186
plan, as defined via its incident fluence x, may lead to different dose distributions187
in the patient. Uncertainty in D models geometric uncertainty such as setup errors,188
organ motion, and range errors.189
2. Uncertainty in the realized fluence x. This would mean that the treatment machine190
does not accurately deliver the fluence specified by the treatment plan. This191
uncertainty is typically considered small compared to uncertainty in the dose-192
influence matrix since the accuracy of fluence delivery can be verified during193
machine QA. The work by Bertsimas et al [5] applies robust optimization to194
uncertainty in the realized fluence.195
3. Uncertainty in q. This can be interpreted as uncertainty in the mathematical196
definition of what a good dose distribution is. q could, for example, represent197
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uncertain parameters in a TCP or NTCP model, uncertainty in target delineation,198
or uncertainty in dose prescription. This is generally considered a large source of199
uncertainty, however, convincing applications of robust optimization in that context200
are limited.201
Robust optimization applied to geometric uncertainty, i.e. uncertainty in the dose-202
influence matrix D has been studied most widely and is the focus of this review.203
For simplicity of notation we assume that geometric uncertainty is modeled through204
discrete error scenarios indexed by k. Each error scenario corresponds to a different205
dose-influence matrix Dk, which yield distinct dose distributions206
dk = Dkx (4)207
Hence, rather than assuming that a fixed dose-influence matrix D relates a fluence map208
x to a predictable dose distribution d, the dose distribution that will finally be delivered209
to the patient is unknown and may be given by any distribution dk. How the scenario210
dose distributions dk are calculated depends on the uncertainty under consideration and211
is further described in sections (4-6).212
3.3. Formal approaches to robust planning213
The next question is how the set of scenario dose distributions dk can be incorporated214
into treatment planning. Each dose distribution dk corresponds to an objective function215
value fk = f(dk), which serves as a measure of treatment plan quality for error scenario216
k. Intuitively speaking, a treatment plan that is both good and robust yields a dose217
distribution dk, which is good for all or the majority of error scenarios that may occur.218
There are different paradigms to translate this notion into mathematical terms. Broadly,219
these approaches can be categorized as follows:220
1. The stochastic programming approach optimizes the expected plan quality.221
2. The minimax approach optimizes plan quality for the worst error considered.222
The stochastic programming approach and the minimax approach can be seen as223
extreme cases. In reality, one may be interested in controlling plan quality in between224
worst-case and average. Therefore, a third category of intermediate approaches should225
be considered. In this section, we formally define the different approaches; applications226
to specific uncertainties in IMRT and IMPT are discussed in sections (4-6).227
3.3.1. Stochastic programming: In the stochastic programming, each error scenario is228
associated with an importance weight pk. The approach then minimizes the expected229
value of the objective function:230
minimize
x
∑
k
pkf(d
k(x)) (5)231
The scenario weights pk are often interpreted as the probability that error scenario k232
occurs. Hence, the stochastic programming approach minimizes the objective function233
Robust radiotherapy planning 7
evaluated for all error scenarios, while more weight can be given to scenarios that are234
likely to occur and lower weight to extreme scenarios that are unlikely. In this review,235
we will refer to the parameters pk as probabilities, however, it is worth noting that236
the application of equation 5 does not depend on such a probabilistic interpretation.237
The parameters pk can simply be interpreted as weighting factors that indicate how238
important it is to achieve good plan quality for error scenario k. The stochastic239
programming approach is sometimes referred to as probabilistic planning, however, the240
term probabilistic is more broadly used also for other approaches that assign probability241
distributions to error scenarios. Stochastic programming has been widely applied in242
both IMRT [6, 7, 8, 9, 10] and IMPT [11, 12].243
3.3.2. Minimax optimization The minimax approach aims at obtaining the treatment244
plan that is as good as possible for the worst error scenario that is considered:245
minimize
x
max
k
[
f(dk(x))
]
(6)246
Here, the maximum of the objective function over the error scenarios k is taken, which247
is minimized with respect to the incident fluence. In this case, no importance weights248
pk are defined and the treatment plan only depends on the set of error scenarios. The249
approach is also referred to as worst-case approach. Minimax optimization has mostly250
been investigated in IMPT planning [13].251
3.3.3. Minimax stochastic programming: The probabilistic approach and the minimax252
approach are related in the sense that a specific set of scenario weights pk in the253
probabilistic approach yields the solution to the minimax formulation, namely such254
scenario weights that assign high pk to the most unfavorable scenarios. The two methods255
can be interpreted as special cases of the minimax stochastic programming problem [14],256
which is defined as257
minimize
x
max
p∈P
∑
pkf(d
k(x)), (7)258
where,259
P = {p : 0 ≤ pk ≤ ρ,
∑
k
pk = 1} (8)260
is the uncertainty set for the scenario probabilities pk. In words, this problem optimizes261
the expected value of the objective function for the most unfavorable probability262
distribution pk over its uncertainty set. The parameter ρ controls the uncertainty level.263
For ρ = 1 every probability distribution is allowed, and consequently the minimax264
stochastic programming problem (9) is equivalent to the worst-case optimization in265
equation (6). For the choice ρ = 1/K, where K is the number of scenarios, we obtain266
the probabilistic approach (5) where equal importance pk = 1/K is assigned to all267
error scenarios. By selecting 1/K ≤ ρ ≤ 1 one can gradually transition between the268
stochastic programming and worst-case formulation. This approach is also referred as269
distributionally robust approach.270
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For the parameter choice ρ = 1/(αK) where 1/K ≤ α ≤ 1, minimax stochastic271
programming (9) is equivalent to what is referred to as conditional value at risk (CVaR)272
optimization with parameter α [14, 15, 16]. In CVaR optimization, the average of the273
fraction α of the worst scenarios is minimized. For example, for α = 0.1 one would274
optimize the average plan quality for the worst 10% of scenarios, neglecting the 90% of275
more favorable scenarios.276
←∑k pkfk
P
ro
b
ab
il
it
y
f
(a) Stochastic programming
←∑k pkfk ← maxk fk
P
ro
b
ab
il
it
y
f
(b) Minimax optimization
fmin
P
ro
b
ab
il
it
y
f
(c) Minimax stochastic optimization
fmin fmax
P
ro
b
ab
il
it
y
f
(d) Maximizing chances of correct treatment
Figure 1. Schematic illustration of different robust planning approaches. Uncertainty
and a large number of error scenarios lead to a probability distribution over the
objective function value, which serves as a plan quality indicator. The figures sketch
the probability distribution (on the vertical axis) over objective function values (on
the horizontal axis). Red dotted lines indicate an improved distribution, compared to
black distributions, that the respected method is striving for. See Section 3.3.4 for
discussion of (a-c) and Section 3.4.2 for discussion of (d).
3.3.4. Graphical illustration Let us interpret the scenario weights pk as probabilities277
for the error scenario k to occur. If a large number of scenarios is considered, this results278
in a probability distribution over dose distributions dk and consequently a probability279
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distribution over objective function values fk = f(dk). Figure 1 schematically illustrates280
the above approaches. Figure 1a assumes the stochastic programming approach for an281
objective function f ≥ 0 such as an NTCP function or the quadratic objective function to282
achieve a homogeneous target dose. The stochastic programming approach (equation 5)283
minimizes the mean of the distribution of objective function values, but not necessarily284
the tail towards large values. The treatment plan may allow for large objective function285
values for individual error scenarios, possibly corresponding large errors that are unlikely286
to occur. In contrast, the minimax approach (equation 6) only optimizes the maximum287
value of the distribution as illustrated in figure 1b. This usually requires that the set288
of error scenarios is truncated towards large errors. In addition, the minimax approach289
does not per se aim at improving the average objective value. The CVaR approach290
(figure 1c) represents an intermediate approach. It can be interpreted as a relaxation of291
the minimax method: unfavorable scenarios are emphasized without focusing purely on292
the worst case. Thereby, a small number of scenarios can have higher objective values293
for the benefit of better plan quality for most other scenarios.294
3.4. Variations of these approaches295
3.4.1. Robust constraints: Above, approaches for incorporating uncertainty in the296
objective function were considered. In addition, a treatment plan optimization problem297
may have constraints on the dose distribution. The most obvious approach for298
robustifying constraints is to enforce that the constraint is fulfilled for all error scenarios.299
This has mostly been investigated in proton therapy with a relatively small number of300
error scenarios, but also in the context of breathing motion [17] (see section 6.2).301
3.4.2. Maximizing the probability of target coverage and OAR sparing: The302
probabilistic interpretation in figure 1 gives rise to variations of the approaches described303
above. One may want to achieve that a DVH criterion for target coverage is fulfilled for304
the majority of patients, for example, that in 95% of the scenarios, 95% of the target305
volume receices the prescribed dose. Similar to that, one may want to maximize the306
probability that a planning criterion is fulfilled. This is schematically illustrated in307
figure 1d. Here, it is assumed that f represents a dosimetric plan quality indicator such308
as an EUD or a DVH criterion. In this case, the goal is to minimize the cumulative309
probability that the value of f falls outside of the desired range, i.e. the probability that310
fk > fmax, the probability that f
k < fmin, or both. For example, if f is the EUD in311
an OAR, one may want to minimize the cumulative probability that the EUD is larger312
than the maximum allowed EUD fmax. Hence the objective function to be minimized313
becomes314
minimize
x
∑
k
pkH(f(d
k(x))− fmax) (9)315
where H denotes the heaviside step function, i.e. H(f(dk(x))− fmax) = 1 if f(dk(x)) >316
fmax and zero otherwise. Such approaches were investigated for interfraction motion in317
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IMRT by Sobotta et al [18] and Gordon et al [19].318
3.4.3. Variations of the minimax approach There are several variations of the minimax319
approach in equation (6). In most practical situations, the objective function f(d) =320 ∑
swsfs(d) is a sum of objectives fs for individual structures s weighted with importance321
factors ws. In this case, it is possible to consider the maximum over scenarios for every322
structure-based objective individually rather than the maximum over the composite323
objective function:324
minimize
x
∑
s
ws max
k
[
fs(d
k(x))
]
(10)325
This has been referred to as the objective-wise worst case, in contrast to the minimax326
approach in equation (6) which has been called the composite worst case. The327
objective-wise worst case approach has advantages in multi-criteria optimization and328
was investigated in that context [20]. Often, the objective function fs(d) =
∑
i∈Is fi(di)329
can further be written as a sum of contributions fi from individual voxels i contained330
in structure s. In this case one can consider the maximum over the scenarios for each331
voxel separately, which leads to the voxel-wise worst case method:332
minimize
x
∑
s
ws
∑
i∈Is
max
k
[
fi(d
k
i (x))
]
(11)333
This method can be interpreted as optimization of the worst-case dose distribution. To334
see this, one can consider the piece-wise quadratic objective function for overdosing of335
an OAR:336
f(d) =
∑
i
(di − dmax)2+ (12)337
The contribution of a voxel i is determined by the maximum dose the voxel may receive338
for any scenario, i.e.339
max
k
[(
dki − dmax
)2
+
]
=
(
max
k
[dki ]− dmax
)2
+
(13)340
Hence, in this case, treatment plan optimization corresponds to evaluating the objective341
function for the worst-case dose distribution, which is defined, voxel-by-voxel, as the342
maximum dose delivered for any scenario. Similarly, a piece-wise quadratic objective343
for target underdosage can be considered, in which case the worst-case dose distribution344
corresponds to the minimum dose in each voxel. This approach was predominantly345
applied in robust IMPT planning [21, 22, 23].346
3.4.4. Other approaches Chu et al. [24] presented another robust planning approach,347
whose starting point is that the dose and its uncertainty can be characterized by the348
expected dose and its variance. The probability that a voxel i in the CTV receives a349
dose higher than a prescribed minimum dose dmin depends on both the expected dose350
(which must be high enough) and the variance (which must be small enough). Assuming351
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k pk = 1, the mean and variance of the dose in voxel i can be estimated based on the352
scenarios as353
E(di) =
∑
k
pkd
k
i (14)354
V(di) =
∑
k
pk(d
k
i )
2 − (E(di))2 (15)355
where the expected dose is a linear function of the fluence x and the variance is a356
convex quadratic function of x. To ensure target coverage under uncertainty with high357
probability, Chu et al. propose a constraint on every voxel in the CTV such that the358
expected dose minus a multiple of the standard deviation exceeds the prescribed dose,359
i.e.360
E(di)− δ
√
V(di) ≥ dmin (16)361
Under the assumption that the dose in voxel i follows a Gaussian distribution (which362
is approximately the case for random errors but generally not for systematic errors)363
the parameter δ can be calculated based on the cumulative distribution function of364
the Gaussian and the accepted probability of underdosing. For example, limiting the365
probability of underdosing to 5% requires δ = 1.64. The constraint (16) can be written366
as367
dmin − E(di)√
V(di)
≤ δ (17)368
which represents a second order cone constraint, which from an optimization perspective369
is almost as computationally efficient as a purely linear constraint. A similar constraint370
can be constructed for voxels in OARs and a maximum dose threshold dmax.371
372
Xie [25] presented a method that considers the expeced value and the variance of373
a general plan quality indicator rather than the dose in a voxel. Assume that fs is a374
plan quality indicator associated with a structure s which has a desired value fpress . Xie375
suggests to minimize376
(E(fs)− fpress )2 + V(fs) (18)377
where E(fs) and V(fs) are expected value and variance of the plan quality indicator,378
which are estimated from the scenarios analogously to equations (14) and (15). In379
the special case that fs is the dose in a single voxel, this method is equivalent to the380
stochastic programming approach using the quadratic objective function as discussed381
in section 4.2. The method is suggested within a prioritized optimization framework to382
trade-off plan robustness against other plan quality measures.383
3.5. General considerations and choice of method:384
Among the different methods described above, no general statement can be made which385
method is superior. Research on handling interfraction motion in IMRT has largely386
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focused on the stochastic programming approach and other methods with probabilistic387
interpretation described in section 3.4.2. In the context of range and setup errors in388
IMPT, both stochastic programming as well as different versions of the worst-case389
method have been studied extensively. Any robust planning to handle specific types390
of uncertainty has to address several problems:391
1. Modeling of the uncertainty. First, the uncertainty to be accounted for is to be392
modeled mathematically. This is straightforward for some types of errors, e.g.393
setup errors, which can be modeled as a rigid shift of the patient with respect to394
the isocenter. However, in other situations, e.g. breathing motion with variations395
in the breathing pattern, it is not immediately clear how to model the uncertainty.396
2. Choosing an adequate method, i.e. formulating the robust optimization problem397
in a meaningful and computationally tractable way.398
3. Developing ways to solve the optimization problem efficiently. This includes ways399
to calculate or approximate the dose distribution dk for a given error scenario.400
The above issues are interrelated. For example, whether a probabilistic or minimax401
approach is taken typically impacts what model of the uncertainty is suited. The worst402
case approach typically requires that the underlying error is truncated. For example, a403
treatment planner would set the maximum setup error to be accounted for. In the prob-404
abilistic approach instead, a setup error can be modeled via a Gaussian distribution,405
containing large errors with low weights pk. Also, the need to devise efficient optimiza-406
tion algorithms influences the formulation of the problem as well as the model of the407
uncertainty.408
409
4. Setup errors and inter-fraction organ motion in IMRT410
In this section we review applications of robust planning for handling of setup errors411
and inter-fraction organ motion in IMRT. In this context, it is customary to separate412
the errors into a systematic component which is constant over all treatment fractions,413
and a random component which varies daily. A systematic error is typically introduced414
during treatment planning; an example is an extreme position of the prostate in the415
planning CT, which differs from the mean position of the prostate. The random error is416
related to daily patient anatomy and setup variations during fractionated treatments.417
418
In section 4.1 we briefly discuss modeling of setup errors and inter-fraction motion.419
In section 4.2 we illustrate the stochastic programming approach applied to a stylized420
phantom, which provides insight into the qualitative features of this approach with421
respect to the handling of systematic and random errors. In the remaining part, we422
review the application to handling inter-fraction prostate motion, which has been the423
focus of most research. In section 4.7 we discuss computational aspects to facilitate424
robust planning at acceptable calculation times.425
Robust radiotherapy planning 13
4.1. Modeling inter-fraction motion uncertainty426
A setup error is usually understood as a rigid shift of the patient with respect to the427
isocenter. Most works in IMRT model setup errors using Gaussian distributions in428
3 dimensions. Inter-fraction motion, for example of the prostate, is generally more429
complex to model. However, to first approximation, inter-fraction motion is often430
modeled as a setup error. This is appropriate if inter-fraction motion is mostly a rigid431
translation of the tumor inside the patient. This model can be improved by adding432
rotations. However, such an approach does not model deformations of the tumor and433
the surrounding anatomy. The most widely used approach for more accurate modeling434
of inter-fraction motion is principal component analysis (PCA) [26]. PCA identifies the435
dominant modes of deformable motion of the target and the surrounding anatomy. It436
yields a parmeterized model of the motion in which a plausible anatomical scenario is437
given by the mean position plus a linear combination of a set of eigenmodes multiplied438
by a scaling coefficient. In the case of prostate, this includes modeling expansion of439
rectum and bladder together with the resulting translation and rotation of the prostate440
in the sagittal plane. PCA modeling has a wide range of applications, including441
prostate dosimetric evaluation [27] and optimization [28] based on virtual treatment442
course simulation, coverage probability estimation [29], adaptive radiotherapy [30], and443
deformation modeling for lung [31]. Specifically for the deformable interfraction motion444
of prostate cancers, there have been several PCA models developed so far. Some models445
statistically model the surface deformations of two to three ROIs only [32, 33, 34]. Some446
other models model the entire 3D pelvic anatomy and therefore they are of more value447
to image guided adaptive radiotherapy applications. These models are either patient-448
specific or population based [35]. In general, the patient-specific models require an initial449
image data collection period to fully characterize the patient-specific motions. At the450
early phase of treatment where the patient data are very limited, the population-based451
model is more advantageous. However, the potential risk is that a population model452
may not benefit every patient if any unusual deformation is involved.453
4.2. Qualitative features of the stochastic programming approach454
The concept of stochastic programming can be illustrated by considering the quadratic455
objective function as an example:456
f(d) =
∑
i
(di − dpres)2 (19)457
where dpres is the prescribed homogeneous target dose and the sum runs over the voxels458
i in the target. Following the stochastic programming approach, the expected value of459
the quadratic objective function can be written as460 ∑
k
pkf(d
k) =
∑
k
pk
∑
i
(
dki − dpres
)2
(20)461
=
∑
i
(E(di)− dpres)2 (21)462
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+
∑
i
(∑
k
pk
(
dki − E(di)
)2)
(22)463
where E(di) is the expected dose in voxel i as in equation (14). This has an intuitive464
interpretation. The first term (21) is the quadratic difference between the expected dose465
and the prescribed dose. Hence, minimizing this term will ensure that the dose will, on466
average, be close to the prescribed dose. The second term (22) represents the variance467
of the dose in each voxel. Minimizing this term will ensure that the dose dki realized in468
a scenario k is close to the expected dose.469
470
We now illustrate the result of stochastic programming using the quadratic objec-471
tive function for a systematic Gaussian setup error in a one-dimensional phantom. The472
error scenarios correspond to shifts of the tumor up to ±10 mm. The probabilities pk473
are chosen from a Gaussian distribution with 3 mm standard deviation. For this illus-474
trative example, a simplified dose-influence matrix is assumed in which each beamlet475
j corresponds to a Gaussian beam profile with 3 mm standard deviation to model the476
penumbra. Setup errors are modeled as a shift of the voxel grid relative to the beamlet477
grid. Treatment plan optimization minimizes the expected value of the quadratic ob-478
jective function, where the prescribed dose dpres is set to 1 for the tumor and zero for479
the adjacent normal tissue.480
481
Figure 2. Illustration of stochastic programming for handling random setup errors
in a one-dimensional phantom. The three panels correspond to a different number of
fractions assumed for plan optimization: 1 fraction (left), 30 fractions (middle), and
infinitely many fractions (right). We consider a 60 mm wide target volume in lateral
direction, 36 beamlets spaced 2 mm apart corresponding to Gaussian beam profiles
with 3 mm standard deviation, and a Gaussian setup uncertainty with 3 mm standard
deviation. The nominal dose profile is shown in blue, the expected value of the dose is
shown in red, and the standard deviation of the dose considering 30 fractions is shown
in green. For comparison, the graphs for 1 and ∞ fractions also includes the standard
deviation for the respective fractionation scheme used for optimization in orange.
A treatment plan which only considers a systematic error (which is equivalent to482
only considering random errors for one fraction) yields a dose distribution which is com-483
parable to a PTV type treatment plan using conventional optimization (figure 2 left).484
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The incorporation of uncertainty into the optimization process induces an automatic485
expansion of the nominal dose (blue) around the CTV so that the expected dose (red)486
yields adequate coverage under uncertainty. Sir et al [36] investigated in more detail487
for systematic setup errors how the shape of the dose fall-off at the edge of the target488
volume depends on the type of objective function.489
490
Next, we consider the case of random setup errors in a fractionated treatment with491
T fractions. An error scenario k now corresponds to a set of T setup errors {k1, . . . kT}.492
The total dose in scenario k is given by493
dki =
1
T
T∑
t=1
dkti (23)494
The probability of an error scenario is given by the product of Gaussian probabilities495
for each fraction. In this case, the goal is to deliver a cumulative dose close to the496
prescription after the entire course of T fractions, whereas the dose in an individual497
fraction is allowed to vary. This leads to qualitatively different treatment plans as il-498
lustrated in figure 2 (middle). The nominal dose, i.e. the dose distribution delivered to499
a static geometry features horns as described in section 2. The treatment plan reduces500
the dose delivered to regions where both tumor and normal tissue can be located. As501
a consequence, the edge of the tumor may be underdosed in some fractions when the502
setup errors are large. However, the horns deliver doses higher than the prescription503
dose in some fractions, which compensates for fractions in which parts of the tumor is504
underdosed.505
506
The height of the horns depends on the number of fractions. For a large number of507
fractions, the horns are more pronounced as more averaging will occur over the course508
of treatment. In the case that only a single fraction is delivered, a random error is509
equivalent to a systematic error in which no averaging occurs. In this case the horns510
disappear (figure 2 left). Mathematically, the number of fractions changes the relative511
weighting of the two terms in the objective function (21). The expected value of the512
dose is independent of the number of fractions while the variance decreases with the513
number of fractions as 1/T [37].514
515
For the hypothetical case that infinitely many fractions are delivered, the expected516
value of the dose distribution is realized. Hence, the uncertainty in the dose distribu-517
tion vanishes. The dose distribution under the influence of random errors is given by518
a convolution of the nominal dose distribution with the probability density function of519
the random error. Treatment planning can be performed analogously to conventional520
treatment planning except that the objective function is evaluated for the expected dose521
rather than the nominal dose. However, this approach emphasizes the horns (figure 2522
right), which leads to dose uncertainty if the plan is delivered in a finite number of523
fractions. Mathematically, this solution can be interpreted as a deconvolution of a step524
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function (the desired ideal dose fall-off at the edge of the target volume) with the Gaus-525
sian probability distribution.526
527
Figure 2 illustrates two main characteristics of the probabilistic approach when528
applied to setup errors. First, the approach allows for automated extension of the529
irradiated region around the target volume without explicitly defing a PTV. Second,530
random errors lead to qualitatively different plans featuring horns. These properties531
of the probabilistic approach have been demonstrated by several authors for stylized532
phantoms. Unkelbach et al [37, 38] considered a 2-dimensional rotation therapy model533
in conjunction with the expected value of the quadratic objective function. Earlier,534
Lind et al [39] and Lo¨f et al [40] considered 1-dimensional phantoms together with535
TCP based objective functions. Recently, Witte et al [41] studied an asymmetric 2-536
dimensional model in which an OAR is located on one side of the tumor. The authors537
investigate the shape of the dose distribution that optimally balances tumor coverage538
and OAR sparing in the context of TCP as well as traditional objective functions. The539
authors also observed that, in the case that the residual random errors are small and are540
incorporated along with systematic errors, the tendency to generate horns is reduced.541
4.3. Stochastic programming applied to inter-fraction prostate motion542
The stochastic programming approach has been demonstrated for realistic patient543
geometries. The majority of these works considered the handling of inter-fraction motion544
of the prostate in IMRT [6, 42, 7, 9] but also head & neck cancer was considered as545
application [10, 43].546
4.3.1. Handling of random errors: The paper by Unkelbach et al [6] and Maleike et al547
[42] apply stochastic programming with a quadratic objective function, which is demon-548
strated for a 1-dimensional phantom in section 4.2, to inter-fractional prostate motion.549
The analysis focuses on the handling of random errors. Qualitatively, the same effects550
can be observed as in figure 2. This includes the presence of horns for standard frac-551
tionated treatments in the static dose distribution that would be delivered to a static552
geometry, especially at the boundary of prostate and rectum. The works by Birkner et553
al [44] and McShan et al [45] investigate the handling of random errors by performing554
treatment plan optimization based on the expected value of the dose, which represents555
an approximation of the quadratic programming approach as described in section 4.2.556
557
In principle, horns represent a mechanism to achieve steeper dose gradients558
at the edge of the target compared to conventional PTV based treatment plans.559
However, today the clinical desirability of dose horns is questionable: averaging out560
the inhomogeneities in the static dose distribution relies on the random errror being561
actually present during fractionated treatment. This may be in conflict with common562
thinking in practice, where the goal is to robustify a treatment plan against potential563
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random errors while simultaneously using all available means to avoid random errors.564
In addition, the work in [6] used relatively large random errors that are unrealistic in565
the era of image guidance. By most researchers, the concept of horns to sharpen the566
dose gradient at the edge of the target in the presence of random errors is therefore not567
considered a promising approach.568
4.3.2. Stochastic programming using physical dose objectives: Stochastic programming569
was more extensively evaluated and compared to PTV based planning by Bohoslavsky570
et al [9] for prostate cancer and by Fontanarosa et al [10] for head & neck cancer.571
Bohoslavsky et al [9] developed an implementation of stochastic programming for572
interfraction motion as a plugin to a research version of the Pinnacle treatment planning573
system. The works optimize the expected value of objective functions typically used in574
clinical treatment planning, quadratic penalty functions and EUD objectives. A main575
finding of these works is that, using these tradiational objective functions, stochastic576
programming for handling systematic errors yields treatment plans that are qualitatively577
similar to PTV based plans. This is consistent with other publications demonstrating578
stochastic programming for systematic errors using quadratic penalty functions [6].579
However, when OARs are located close to the CTV, stochastic programming may be580
used to redistribute dose away from OARs to less critical normal tissues, such that the581
dose to the OAR is lowered while the CTV remains covered under the majority of error582
scenarios.583
In the context of dose painting by numbers, Witte et al [16] describe a modification584
of the stochastic programming approach towards conditional value at risk optimization.585
Instead of calculating the weighted average of the objective function over all scenarios,586
the summation occurs only over a subset of the scenarios. At each iteration of a gradient587
based optimization method, the scenarios are ranked according to their objective value.588
The summation is performed only over the better 90% of scenarios while neglecting589
the 10% of scenarios with the highest objective values. The method was applied to a590
quadratic penalty function with the goal of delivering at least the prescription dose to591
the CTV in 90% of the scenarios. In that sense, the method has similarities to the592
method by Gordon et al [19] described in section 4.5.593
4.3.3. Optimizing expected TCP and NTCP: Stochastic programming using typical594
dose based objective functions, such as quadratic penalty functions, can automate595
the expansion of the irradiated region around the CTV. However, this does still not596
necessarily determine the optimal trade-off between target coverage and normal tissue597
sparing. In principle, stochastic programming is very natural in the context of TCP598
and NTCP based objective functions. A TCP model yields a value of tumor control599
probability for a given dose distribution. Taking the expectation over an uncertain dose600
distribution dk,601
TCP =
∑
pkTCP(d
k) (24)602
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can be interpreted as the overall probability of tumor control taking into account ge-603
ometrical uncertainty. Formally, this corresponds to marginalization over uncertain604
parameters in a probability distribution. Thereby, probabilistic planning could, at least605
in theory, find the optimal trade-off between target coverage and OAR sparing. The606
probabilistic approach applied to inter-fraction motion of the prostate using TCP based607
objective functions has been investigated by Witte et al [7]. One difficulty in evaluating608
the benefit of this approach is that using TCP based objectives usually results in treat-609
ment plans that are different from those used in clinical practice - due to the choice of610
the objective function rather than the way uncertainty is handled.611
612
4.4. Maximizing the probability of adequate treatment613
A variant of the concept outlined in section 3.4.2 was implemented in [18, 46]. In brief,614
the optimization problem was formulated as follows: minimize the cumulative probabil-615
ity that a dosimetric plan quality indicator for the target is worse than a given limit,616
while keeping the cumulative probability below a guaranteed maximum that dosimet-617
ric plan quality indicators for organs at risk are above a given limit. In other words,618
for each plan quality indicator, the objective or constraint is specified via a minimum619
or maximum limit and a maximum cumulative probability that this limit is exceeded.620
Conventional constraints on static plan quality indicators could be added.621
622
Naturally, the crux of such a problem formulation lies in the estimation of the tails623
of the probability distributions of each plan quality indicator, which are usually sampled624
sparsely and are hence cost functions with a caveat. Sobotta et al suggest to approximate625
the cumulative probabilities of the tails by Chebyshev’s inequalty, which reduces the626
problem to computing the mean and variance of the quality indicators’ probability627
distributions. Still, for the treatment of inter-fractional uncertainties not satisfying the628
static dose cloud approximation, the computational burden of sampling the uncertainty629
space to estimate mean and variance can nevertheless become overwhelming. Sobotta630
et al further suggested to replace the direct evaluation of the plan quality indicators by631
a substitute patient model and demonstrated the utility of a Gaussian Process for this632
[47]. Other methods of machine learning may be suitable alternatives.633
4.5. Probabilistic optimization of DVH objectives634
A related approach to optimize plan quality for the majority of patients has been sug-635
gested by Gordon et al [19]. The work is motivated by the widespread use of DVH cri-636
teria for treatment plan evaluation, for example, that 95% of the target volume should637
receive the prescribed dose. An intuitive extension of this criteria in the context of638
setup uncertainty is to request that a DVH criterion is fulfilled for a given percentile639
of scenarios. This leads to the concept of percentile dose volume histograms (pDVH).640
In this approach, dv,q denotes the dose that is exceeded in the percentage volume v in641
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q percent of the scenarios. For example, a treatment planning goal can be to obtain a642
plan that delivers the prescription dose to 95% of the target in 90% of the patients, i.e.643
we would like d95,90 to exceed the prescription dose.644
645
A heuristic to obtain such a treatment plan has been suggested by Gordon et al646
[19]. At every iteration during treatment plan optimization, the current treatment plan647
is evaluated by sampling a large number of systematic setup errors and evaluating the648
dose distribution within the static dose cloud approximation. Based on that, dv,q is649
determined. Subsequently, an objective function is introduced that aims to increase650
dv,q to the prescription dose. To that end, a rim structure surrounding the CTV651
is introduced. This rim structures is analogous to a PTV, however, in contrast to652
traditional planning, the method does not aim to deliver the prescribed dose to all of653
the PTV but only to the degree necessary to achieve the desired dv,q. In traditional654
planning, quadratic penalty functions are used as a heuristic to satisfy DVH objectives.655
Assume that the goal is to deliver dpres to v% of the PTV. Further assume that the656
current plan does not fulfill this and that only a lower dose dv < d
pres is exceeded in657
v% of the PTV. Then, a quadratic penalty is introduced for all voxels in the PTV that658
receive a dose between dv and d
pres:659
f(d) =
∑
i∈S
(di − dpres)2+ (25)660
where S = {i ∈ PTV |dv < di < dpres}. Hence, the quadratic penalty is applied to those661
voxels that are underdosed the least. This method can be modified to percentile DVH662
objectives by changing the set of voxels to S = {i ∈ CTV + rim |dv,q < di < dpres}.663
Here, the CTV+rim contains the voxels that play a role in achieving CTV coverage.664
Intuitively, it is clear that voxels close to the CTV are more important to ensure CTV665
coverage under the influence of errors, compared to voxels further away from the CTV666
edge. This can be incorporated by introducing voxel-dependent penalty factors in equa-667
tion (25) such that voxels close to the CTV are weighted more than voxels further away.668
669
With the same goal in mind [48] presented an extension to the work of [19] where670
they transferred the DVH-based coverage objectives into coverage constraints. Thereby671
they suggest a robust planning process that implements probabilistic constraints to avoid672
probabilistic criteria being traded in against competing objectives during optimization.673
674
4.6. Optimization based on probability of tumor and organ presence675
Baum et al [49] suggested a practical and computationally efficient method for handling676
systematic errors due to setup or inter-fraction organ motion. The method can be677
derived from the stochastic programming approach (equation 5) by a shift of perspective678
[50]. Robust planning methods as introduced in section 3 evaluate the dose in the679
patient’s own coordinate system, where the dose becomes a random variable. Instead,680
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the approach by Baum et al considers the dose distribution in the treatment room681
coordinate system, which is constant within the validity of the static dose cloud682
assumption (section 4.7.1). Setup errors and inter-fraction motion can be modeled683
as a change in the segmentation of the planning CT into CTV and OARs, i.e. an error684
changes the set of voxels that belong to the CTV or an OAR. For each voxel i, the sum685
of all scenario probabilities pk for a scenario k where i is occupied by a given structure686
corresponds to the probability that the voxel belongs to that structure, which Baum687
et al defined to be the coverage probability qi. For any voxel-separable objective, these688
probabilities can be used as voxel-specific weighting factors in the objective function.689
For example, a quadratic penalty function for the CTV becomes690
f(d) =
∑
i
qi (di − dpres)2 . (26)691
This short derivation shows that the method essentially optimizes the mean objective692
function, averaged over all considered systematic errors. Optimization of this objective693
aims at delivering the prescribed dose to all voxels that may be occupied by the CTV694
or organ. However, if the probability is low, these voxels are weighted less. Hence,695
treatment plan optimization will preferentially lower the dose to voxels of the CTV if696
in conflict with other normal tissue objectives. The method has the advantage of being697
computationally efficient, adding a mere weight to every voxel of a classic static PTV698
or PRV patient model. Under certain conditions, namely validity of the static dose699
cloud approximation and voxel-separable objectives, this approach is mathematically700
equivalent to the stochastic programming approach for handling systematic errors.701
This has been shown for the quadratic objective function in [50]. While equation702
(26) describes the concept for achieving coverage of the CTV, the method is equally703
applicable to OAR objectives. In this case, qi is the probability of voxel i being occupied704
by a certain OAR.705
4.7. Computational considerations706
4.7.1. Static dose cloud approximation: Application of robust planning techniques707
requires the evaluation of the dose distribution dk for all scenarios under consideration.708
It would be possible to invoke the dose calculation algorithm several times and709
calculate a dose-influence matrix Dk for each error scenario. This would however be710
computationally and memory-wise expensive. Therefore, the dose distribution for an711
error scenario k is often approximated based on the nominal dose distribution. In photon712
therapy, approximate dose calculation of a voxel is based on the assumption that the713
effect of setup errors or inter-fraction motion can be approximated as a shift of the voxel714
relative to the nominal dose distribution. Let D(r) denote the nominal dose distribution715
as a function of the position r in 3-dimensional space, so that di = D(ri) is the dose at716
voxel i whose center is located at position ri. For an error scenario k, corresponding to717
setup error ∆rk, the dose in voxel i is approximated as dki = D(ri−∆rk). The underlying718
assumption is that a setup error or a change of the patient geometry leaves the dose719
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distribution D in space unaffected, which has also been called the static dose cloud720
approximation. This is usually an acceptable approximation in photon therapy [51].721
For proton therapy, this approximation breaks down and improvements are discussed in722
section 5.5.723
4.7.2. Dose blurring for handling random errors: Many works approximate the effect724
of random errors via a convolution of the static dose cloud D with the probability725
distribution of a setup error, which is also referred to as dose blurring. In other726
words, this means that dose distribution resulting from random errors in T fractions727
as in equation (23) is replaced by the expected value of the dose and thereby becomes728
deterministic. This is valid for a treatment with infinitely many fractions and can be729
an acceptable approximation for standard fractionated treatments. However, it breaks730
down when the number of fractions is small. A related but different approximation731
strategy does not perform its random error blurring on the 3D dose distribution,732
but rather on the 2D fluence, projecting the errors in the patient’s coordinate frame733
onto the planes perpendicular to each beam direction [52]. This fluence convolution734
approach may better handle those situations in which heterogeneous densities or air-735
tissue interfaces render the static dose cloud approximation invalid. While dose blurring736
is a good strategy for treatment plan evaluation, it should be noted that treatment plan737
optimization based on blurred dose distributions leads to the horns discussed in section738
4.2, which may not be desired. Moore et al [53] demonstrated optimization incorporating739
fluence-convolution and found reduced OAR doses compared with margin-based plans.740
4.7.3. Computational burden of robustness evaluation: Several approaches use741
sampling techniques to estimate the probability distribution over objective function742
values at each iteration [19, 18]. When dose distributions for errors are approximated743
by the static dose cloud approximation, it is interesting to note that the computation744
time needed to evaluate the probability distribution over objective function values is745
substantially less than one may intuitively expect. This is because the computation time746
is dominated by calculating the nominal dose distribution from the beamlet intensities.747
Using a typical beamlet size of 5 mm, an IMRT or VMAT plan may contain in the748
order of 10’000 beamlets. Hence, calculating the nominal dose to a single voxel requires749
10’000 multiplications and additions. However, the nominal dose distribution needs to750
be calculated only once at each iteration during treatment plan optimization. Even751
if 10’000 dose distributions for errors are sampled subsequently, the computation time752
remains at the same order of magnitude [9].753
5. Systematic range and setup errors in IMPT754
Proton therapy has to deal with all the uncertainties encountered in photon therapy.755
However, there are two main additional challenges in proton therapy:756
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1. Range uncertainty. The finite range of protons is the main advantage of protons757
over photons, however, the exact position of the Bragg peak inside the patient is758
uncertain. To a large extent, range uncertainty arises from the problem that the759
planning CT image is an imperfect input for proton dose calculation. Imaging760
artifacts may corrupt the calculation of radiological depth, and the conversion of761
Hounsfield numbers to relative proton stopping power is not exact. In addition,762
pencil beam dose calculation algorithms widely used to reduce computation time763
compromise dose calculation accuracy in heterogeneous tissue compared to Monte764
Carlo algorithms.765
2. The impact of setup errors and organ motion on the dose distribution tends to be766
more detrimental in proton therapy compared to photon therapy. This is in parts767
because changes in the geometry may lead to misalignment of tissue heterogeneities768
in the beam entrance path and thereby cause changes in the range or degradation769
of the Bragg peak. Therefore, setup errors do not simply lead to a shift of the dose770
distribution in the patient but may severely degrade the dose distribution.771
Practitioners have always been aware of range uncertainties and proton-specific772
strategies to uncertainty handling were developed. These methods are more diverse773
and go beyond the PTV concept used in photon therapy. This includes the choice of774
beam directions that avoid areas of large tissue heterogeneities in the entrance path775
and avoid placing the distal field edge in front of an OAR. For the passive scattering776
technique, range uncertainty was addressed by increasing range and modulation of777
a spread-out bragg peak; setup uncertainty is addressed by widening the aperture;778
and compensator smearing is applied to account for misalignment of heterogeneities779
in the beam entrance path. Additional methods include the use of multiple patch field780
combinations to mitigate potential dose errors at the patch line. Interestingly, treatment781
planning and plan evaluation for passively scattered proton therapy was usually not782
based on a PTV concept. It has been suggested early on to evaluate treatment plans783
using multiple errors scenarios rather than evaluating PTV coverage [54]. In contrast784
to passively scattered proton therapy, treatment planning for pencil beam scanning785
proton therapy is nowadays based on mathematical optimization techniques. In that786
context, the PTV concept was applied in proton therapy, however, its inadequacy as the787
only means of uncertainty handling has been recognized. One of the main additional788
heuristics to achieve robustness is the single field uniform dose (SFUD) concept. As the789
name suggest, each individual beam direction delivers a uniform dose to a PTV, which790
typically reduces the sensitivity to range and setup errors. However, the SFUD technique791
sacrifices some of IMPT’s potential for optimal sparing of normal tissues, especially792
for complex shaped target volumes that wrap around OARs. Over the past years,793
robust optimization methods for IMPT have been developed and are now implemented794
in several commercial treatment planning systems.795
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5.1. Limitations of the PTV concept in IMPT796
The limitations of a PTV concept for handling range uncertainty are illustrated in figures797
3a and 4a. The figures show an ependymoma patient treated with 3 fields. Gaussian798
pencil beams with an initial beam width of approximately 5 mm sigma have been used,799
corresponding to the latest generation of proton machines. Treatment planning aims800
at delivering a dose between 54 and 57 Gy(RBE) to the PTV using quadratic penalty801
functions. The PTV consists of a 2 mm isotropic expansion of the CTV. Additional802
objectives are quadratic penalty functions to limit the maximum dose in the brainstem803
to 54 Gy and for achieving conformity, minimization of the gEUD in the brainstem, and804
minimization of the mean dose in normal brain.805
806
Figure 3. Three-beam IMPT plans for an ependymoma patient. (a) conventional
PTV based treatment plan; (b) IMPT plan optimized for range uncertainty using
the stochastic programming approach. Shown are the dose contributions of the three
beams. The cumulative dose is shown in figure 4.
Figure 3a shows the contributions of the 3 fields. IMPT optimization tends to807
yield highly inhomogeneous dose contributions of individual fields. This is especially808
true if treatment planning aims at minimizing dose to healthy tissues. In this exam-809
ple, minimizing the mean dose in the normal brain leads to a preferential use of bragg810
peaks located at the distal edge of the target volume because these fields deliver dose to811
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the tumor for free while traversing the target volume. Figure 4a shows the cumulative812
dose distribution (left) together with the dose degradation observed for range overshoot813
(middle) and undershoot (right). A range error leads to a misalignment of the dose814
contribution of the three fields. In the case of a range overshoot (i.e. the range is larger815
than expected), the three dose contributions are shifted apart, leading to cold spots in816
the CTV. A range undershoot causes the dose contributions to be shifted closer together.817
This leads to increased doses in parts of the target volume, which may be undesirable818
in locations where the CTV overlaps with the brainstem. In both cases, range errors819
lead to inhomogeneous dose distributions within the target volume, a problem that can820
not be solved by PTV margins alone without additional heuristics such as SFUD.821
822
Figure 4. Robustness analysis of the IMPT plans shown in the figure 3. (left) nominal
dose distribution; (middle) range overshoot; (left) range undershoot. Range over- and
undershoot is modeled by down- and upscaling of the CT Hounsfield numbers by 4.6%.
Similarly, setup errors may lead to substantial degradation of the dose distribution823
rather than a simple shift of the dose as is approximately the case for photons [55, 12].824
This has two reasons. First, a setup error has a different impact on each beam.825
Therefore, a setup error leads to misalignment of dose contributions similar to range826
uncertainties as illustrated above. This effect may occur even in homogeneous tissue.827
Second, setup errors may lead to misalignment of tissue heterogeneities. This is further828
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discussed in section 5.5. The degree of dose degradation depends on the amount of dose829
modulation in the dose contributions of individual beams and tends to be more severe830
the steeper dose gradients in these dose contributions are [56].831
5.2. Qualitative features of robust planning832
Important qualitative features of robust planning are illustrated in figures 3b and 4b.833
The stochastic programming approach is applied to robustify the IMPT plan of the834
ependymoma patient to range uncertainties. Uncertainty is modeled via 3 scenarios:835
the nominal scenario with a scenario weight of 0.5, and one scenario for range over-836
and undershoot with a weight of 0.25 each. Range errors are modeled by down- and837
upscaling of the CT hounsfield units by 4.6%. Features of robust planning for range838
uncertainty include:839
• Dose gradients in beam direction in the dose contributions of individual beams are840
reduced. As a consequence, shifting these dose contributions in beam direction841
within the patient has a reduced impact on their cumulative dose distribution.842
• The region proximal and distal to the CTV is irradiated to cover the CTV for range843
over and undershoot. In contrast to an isotropic PTV margin, the exansion of the844
irradiated region is created in a beam direction specific manner and depending on845
the dose contribution of the beam.846
These features have been discussed in many early publications on robust planning847
[11, 21, 13]. Adding error scenarios for setup errors further modifes the treatment plan848
by expanding the irradiated region lateral to the CTV and by reducing dose gradients849
in the dose contributions of individual fields perpendicular to the beam direction [21].850
5.3. Summary of robust IMPT planning publications851
For IMPT planning, a large variety of methods have been studied. Table 1 provides an852
overview of publications focusing on those publications that introduce novel methods.853
The table summarizes the method used , the type of uncertainty accounted for, and the854
tumor site considered. So far, most works consider systematic range and setup errors.855
In recent years, a significant number of publications appeared that evaluate previously856
published methods or commercial implementations for various treatment sites [57, 58, 59,857
60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 15, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83].858
• Unkelbach et al [11] published one of the first papers on robust IMPT planning.859
The work demonstrates stochastic programming as well as a voxel-wise worst case860
method for handling range uncertainty. The methods are demonstrated for a two-861
dimensional horseshoe shaped phantom and the qualitative features of robust plans862
are discussed.863
• Pflugfelder et al [21] suggested the method of treatment plan optimization based864
on the worst-case dose distribution, corresponding to the voxel-wise worst case865
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Paper Uncertainty Method Tumor site
Unkelbach [11] range SP, vWC 2D horseshoe phantom
Pflugfelder [21] range + setup vWC paraspinal
Moravek [84] dose alg. heuristic lung
+ organ motion
Unkelbach [12] range + setup SP paraspinal
Fredriksson [13] range + setup cWC lung, paraspinal, prostate
Inaniwa [85] range + setup heuristic cervix, 2D phantom
Inaniwa [86] range + setup heuristic prostate
Cao [87] range + setup vWC prostate, skull base
Chen [20] range + setup oWC chordoma, skull base
Fredriksson [88] range + setup SP, cWC, MSP 2D horseshoe phantom
Liu [89] range + setup vWC prostate, skull base
Liu [22] range + setup vWC lung, prostate, skull base
Bangert [90] range + setup SP 2D horseshoe phantom
Liu [91] range + setup vWC head&neck
Petit [92] range vWC liver, lung
Fredriksson [93] setup oWC lung, prostate
Liu [94] range + setup vWC base-of-skull
Fredriksson [95] setup cWC, oWC, vWC prostate
Liu [96] range + setup vWC lung
Liu [97] range + setup vWC lung
+ organ motion
Bokrantz [98] range + setup SP lung, prostate, 3D phantom
+ organ motion
An [15] range + setup SP lung, prostate, head&neck
Wahl [99, 100] range + setup SP prostate, paraspinal, intracranial
Table 1. Overview of publications on robust IMPT planning, summarizing the method
used, the uncertainties addressed and the treatment site used for demonstration.
SP = stochastic programming; cWC, vWC, oWC = minimax optimization in the
flavors composite, voxel-wise, and objective-wise worst case; MSP = minmax stochastic
programming.
method as described in section 3.4.3. The uncertainty model includes range and866
setup errors, modeled via 9 scenarios. The method is demonstrated for a horseshoe867
shaped tumor surrounding the spinal cord. The method was then further studied868
by Liu et al [89, 22] and evaluated for several tumor sites including head & neck869
[91], base-of-skull [94], and lung [96, 97].870
• Fredriksson et al [13] introduced minimax optimization to IMPT optimization and871
demonstrated the method to a lung, prostate, and paraspinal tumor.872
• Chen et al [20] investigated the objective-wise worst case method in the context873
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of multi-criteria optimization (MCO). In this case, the worst case is evaluated for874
each individual objective, which makes the method suited for MCO.875
• Fredriksson [88] describes the minimax stochastic programming model that876
can continuously interpolate between the minimax and stochastic programming877
approach. The three methods are compared for a for a two-dimensional horseshoe878
shaped phantom.879
• Knowing the qualitative features of robust plans can be used to develop heuristics880
for robust treatment planning. Inaniwa et al [85, 86] add terms to the objective881
function that suppress in-field dose gradients and pencil beams that may deliver a882
high dose to an OAR, instead of performing scenario based robust optimization.883
This provides some of the benefits of robust optimization at significantly reduced884
computational cost.885
• Bangert et al [90] devised an analytical probabilistic modeling framework bypassing886
sampling for stochastic programming. A fully Gaussian parameterization of887
the underlying dose calculation enables closed form computation and hence888
optimization of the expected value of the quadratic objective function.889
• Bokrantz and Fredriksson [98] introduced a scenario-based method that is890
equivalent to geometric margins if the scenario doses are calculated using the static891
dose cloud approximation. If more accurate scenario doses are used, then the892
method provides a comparable level of robustness as the minimax and stochastic893
approaches while simultaneously avoiding some of their disadvantages.894
5.4. Comparison of methods895
For handling range and setup errors in IMPT, a large variety of robust planning methods896
has been studied. So far, there is no consensus that one particular method is generally897
superior. To first approximation, all methods provide the same fundamental advantage898
over margins, i.e. the use of scenario dose distributions dk that provide a physically899
realistic model of the dosimetric effect of errors. Thereby, misalignments of tissue het-900
erogeneities or dose contributions of individual fields are accounted for irrespective of901
whether stochastic programming, minimax optimization or an intermediate approach is902
taken. That stochastic programming and worst-case approaches can give qualitatively903
similar results is a finding originally presented by Unkelbach et al [11].904
905
On a more detailed quantitative level, different methods may or may not yield dif-906
ferent results depending on geometry, uncertainty, and planning objectives. The most907
extensive comparison of robust planning methods is provided by the publications of908
Fredriksson and Bokrantz [95, 101, 98], showing that some methods may yield undesir-909
able results in specific situations. Figure 5 illustrates this for the case of setup errors.910
Figure 5a shows the planned dose for a prostate target without OARs in its vicinity.911
The depicted results were generated by optimization with respect to quadratic penalties912
on deviation from the prescription dose within the target and deviation from zero dose913
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elsewhere. The weight for healthy tissue sparing was set small enough as not to com-914
promise target coverage. Systematic setup shifts were discretized into scenarios using915
a uniform grid with a step size of 1/3 cm. Shifts up to 1 cm in 3D were accounted916
for in the optimization, which resulted in 123 scenarios in total. The uncertainty for917
the probabilistic formulation was assumed to follow a Gaussian distribution with 5 mm918
sigma that was truncated at two standard deviations. Stochastic programming (left)919
and minimax optimization (right) yield almost identical results (figure 5a).920
921
Figure 5. Comparison of stochastic programming (left) and minimax optimization
(right) for a prostate cancer case. The figures show a sagittal slice. In (a) all normal
tissue surrounding the target is weighted equally. In this case, both robust planning
approaches yield almost identical treatment plans. In (b) dose to the rectum is
penalized more such that target coverage is compromised for a setup error in posterior
direction. In this case, the two approaches yield distinct results.
A clearer distinction can be made when the desired target dose must be compro-922
mised due to adjacent OARs. This may yield circumstances when the worst-case ap-923
proach has undesired consequences. Figure 5b shows the same example as that shown924
in Figure 5a, except that the objective function f is augmented with a term that em-925
phasizes sparing of the rectum. The weight for this term was set high enough to be926
in considerable conflict with target coverage. The depicted results show that the mini-927
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max method can unnecessarily neglect easy scenarios where target coverage need not be928
compromised (shifts along the inferior-superior axis) if a severe conflict between targets929
and OARs exist under other scenarios (shifts along the posterior-anterior axis). A sim-930
ilar example can be found in Fredriksson et al [95]. These examples illustrate that the931
worst-case approach is more sensitive to the definition of the uncertainty set than the932
probabilistic approach. To resolve conflicts between OAR sparing and target coverage,933
the minimax approach may require explicit selection of the scenarios against which to934
be robust.935
936
The choice of robust planning method may also take the formulation of the objective937
function f into account. If the objective function is a probability measure, such as TCP938
or NTCP, the stochastic programming approach is more natural as described in section939
4.3.3. Similarities with a PTV margin regarding how target coverage is traded against940
OAR sparing may be an argument in favor of the worst-case approach if treatment plan941
optimization is performed with respect to standard physical penalties such as those used942
in Figure 5a. Further examples that compare the stochastic programming and minimax943
approaches with respect to physical penalties can be found in Fredriksson et al [101]944
and Bokrantz et al [98].945
5.5. Approximation of error dose distributions946
To quantify the effects of possible errors, robust radiotherapy planning methods require947
the dose distributions dk under multiple error scenarios. In photon therapy, these948
are often approximated based on the static dose cloud approximation as described in949
section 4.7.1. In proton therapy, this approximation is usually insufficient. This section950
outlines some of the advanced methods for calculating or approximating scenario dose951
distributions dk. The results of the methods are illustrated for scenario dose calculation952
for a systematic setup error on a lung case that has been planned with a 5 mm PTV953
rather than any robust treatment planning method. The nominal dose in a transversal954
slice for this case is shown in Figure 6a. Because of the heterogeneous density of the955
treatment site and the failure to use robust treatment planning, it is expected that the956
dose under the setup error will be deformed compared to the nominal dose, and no957
longer cover the target.958
5.5.1. Separate dose-influence matrices The most accurate way of determining the959
effects of errors on the dose distribution is to perform an accurate dose calculation960
under each scenario. Separate dose-influence matrices are then stored for each scenario961
during the optimization. The dose under each scenario is as accurate as the nominal962
dose. The method is expensive in terms of memory and computation time, however,963
this could be addressed through high-performance computing. Figure 6b shows the964
accurately calculated dose under a setup shift of 5 mm to the patient’s right (left side965
of the image). Because of the heterogeneous density of the site, the dose deforms as an966
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Figure 6. Comparison of different methods to approximate error dose distributions
in IMPT for a 5 mm setup error to the patient’s right (left side of the image). Changes
of the radiological depth along the path of a proton pencil beam resulting from a setup
error are approximated well only by a subset of methods.
effect of the error. In this example, this leads to a cold spot in the distal part of the967
target volume.968
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5.5.2. Voxel shifting methods: A computationally cheap way of calculating scenario969
doses is to perform transformations of the nominal dose distribution. In this case, the970
dose to a voxel for a given error is approximated based on the nominal dose to a different971
voxel. Here, three methods of doing so are presented.972
1. The static dose cloud approximation: This method is described in Section 4.7.1973
and has been extensively used for photons. Figure 6c shows the dose distribution974
according to the static dose cloud approximation under a setup shift of 5 mm to975
the patients right. Because the static dose cloud approximation does not deform976
the dose, it reflects the effect of the setup error poorly. Its γ(3%/3 mm) pass rate977
for voxels with accurately calculated dose above 10% of its maximum was 88.7%.978
2. The static dose cloud approximation per beam: The static dose cloud979
approximation can be improved based on the observation that a setup shift affects980
the dose contribution from different beam directions differently. For example, a981
setup shift along the beam direction does only marginally affect the dose delivered982
by this beam, but impacts the dose from other beam directions. Therefore, a setup983
error may, even in the absence of tissue heterogeneities, lead to dose degradation984
due to misalignment of the dose contributions from different beams. To account for985
this, the static dose cloud approximation can be applied to each beam separately986
by calculating an effective voxel shift taking into account the direction of the setup987
error, the beam direction, and the orientation of the patient’s surface [12]. Figure988
6d shows the dose distribution according to the static dose cloud approximation989
per beam under a setup shift of 5 mm to the patient’s right. For the lung patient,990
the dose difference indicates that there is little benefit in using the static dose991
cloud approximation per beam as compared to the standard static dose cloud992
approximation. Its γ(3%/3 mm) pass rate for voxels with accurately calculated993
dose above 10% of its maximum was 90.2%. This is because the dose degradation994
is dominated by the misalignment of tissue heterogeneities (which is not accounted995
for) rather than the misaligment of dose contributions from different fields.996
3. Voxel shifting accounting for radiological depth: A further improved voxel shifting997
method takes the radiological depth into account during the voxel shifting. The998
beam dose to each voxel is not only shifted according to the setup error projected999
onto the plane perpendicular to the beam central axis, but is also shifted in the1000
direction parallel to the beam to a point with the same radiological depth as the1001
voxel had prior to the shifting [102]. Figure 6e shows the dose distribution according1002
to the voxel shifting method taking radiological depths into account under a setup1003
shift of 5 mm to the patients right. The approximated dose reflects the deformation1004
that occurs due to the setup shift. Its γ(3%/3 mm) pass rate for voxels with1005
accurately calculated dose above 10% of its maximum was 99.4%.1006
5.5.3. Beamlet shifting: Beamlet shifting moves the approximation from the voxel1007
domain to the fluence domain. This way, the dose calculation algorithm’s ability to take1008
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the density distribution of the patient into account is utilized also for the scenario dose1009
calculation, but the computational effort is still much reduced compared to calculating1010
full dose-influence matrices for each scenario. In the beamlet shifting method, a setup1011
error is approximated as a shift of the spot weights (in a fixed spot grid) according to1012
the setup error projected onto the plane perpendicular to the beam. The spot weights1013
at the lateral edges of the spot grid are to be shifted to spots outside the spot grid,1014
which necessitates the calculation of the dose of virtual spots in an extended spot grid,1015
i.e. spots that are only used in the scenario dose calculation but are excluded from the1016
plan. Moreover, if the spots are shifted to positions for which no dose-influence has1017
been calculated, interpolation must be used. To improve on the interpolation, virtual1018
spots can be calculated between the planned spot positions [12]. Figure 6f shows the1019
dose distribution according to the beamlet shifting under a setup shift of 5 mm to the1020
patient’s right. Its γ(3%/3 mm) pass rate for voxels with accurately calculated dose1021
above 10% of its maximum was 99.8%. The differences between the doses arise because1022
shifting of beamlets does not account for beam divergence. Thus, the greater the source1023
axis distance, the smaller the approximation becomes.1024
5.5.4. Approximate dose calculation for range errors All approximation methods1025
except the static dose cloud can handle range errors. The static dose cloud per beam1026
would shift each beam dose longitudinally using geometric depth; static dose cloud with1027
radiological depth would shift each beam dose longitudinally using radiological depth;1028
beamlet shifting would shift the spot weights to other energy layers. For all methods,1029
the distance shifted is a function of depth or energy.1030
5.6. Analytical probabilistic modeling1031
In section 3, approaches to robust planning are formulated using a discrete set of error1032
scenarios. In some applications, the set of error scenarios has been small. For example,1033
in IMPT robust planning models with 9 error scenarios have been studied, consisting1034
of the nominal scenario, range overshoot, range undershoot, and 6 setup errors. In1035
IMRT applications a much larger number of scenarios is typically considered to more1036
accurately represent a Gaussian distribution. In any case, errors are discretized for nu-1037
merical integration. Analytical probabilistic modeling [90] is an alternative approach for1038
uncertainty quantification, which is primarily studied in the conjunction with stochas-1039
tic programming. The main idea behind analytical probabilistic modeling is to use a1040
functional parameterization of pencil beam dose distributions via Gaussian distribu-1041
tions. Using also Gaussian distributions for range and setup errors enables closed-form1042
integration to directly compute the expected value and the standard deviation of the1043
dose, and in some cases the objective function value. Consequently, the full continuous1044
probability density describing uncertainty can be incorporated; it is not necessary to1045
compute individual scenarios.1046
1047
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For proton therapy under range and setup uncertainty, analytical probabilistic1048
modeling provides more consistent estimates of the expected value and the standard1049
deviation of the dose at reduced computation times compared to sampling approaches1050
[99]. This translates into computational advantages for stochastic programming using1051
the quadratic objective function [99]. The computational advantages are particularly1052
prominent in the context of fractionated radiotherapy as analytical probabilistic model-1053
ing allows for a consistent incorporation of random and systematic sources of uncertainty1054
[100]. Recently, it has been shown that the analytical probabilistic modeling framework1055
also generalizes to the non-linear computations of the relative biological effectiveness of1056
carbon ions at the same computational complexity [103].1057
1058
Analytical probabilistic modeling has the potential to enable novel approaches1059
to uncertainty management based on an analytical definition and differentiation of1060
probabilistic objectives and constraints. However, it does not easily generalize to1061
non-pencil beam dose calculation algorithms providing higher accuracy and also the1062
incorporation of uncertainties beyond patient setup and particle range (e. g. anatomical1063
deformations) is an open question.1064
6. Respiratory motion1065
Commonly, motion compensation strategies for handling respiratory motion are divided1066
into 3 types of approaches: 1) gating, where the treatment beam is turned off when1067
the tumors is outside a defined region, 2) tracking, where motion of the treatment1068
couch or the MLC leafs is used to compensate for motion in real time, and 3) safety1069
margin approaches. The latter includes the internal target volume (ITV) approach,1070
where the target volume is defined as the union of the target volumes in all respiratory1071
phases obtained from a 4D CT. An alternative margin approach is the mid-ventilation1072
concept where an appropriate margin is added to the target volume defined in the mid-1073
ventilation phase. A fourth approach that incorporates the motion into treatment plan1074
optimization is often forgotten. Such methods can broadly be divided into two groups:1075
1. Approaches that assume a probability density function (PDF) for the position of the1076
target, which is incorporated into plan optimization. The motion PDF describes1077
the relative amount of time that the tumor spends in each breathing phase. In1078
this case a single treatment plan is created, which is delivered without any online1079
adjustments to motion measured during treatment.1080
2. Approaches that assume that the motion is predictable or monitored in real time,1081
and that the delivery of radiation can be synchronized with the motion.1082
Both approaches have sometimes been referred to as 4D optimization despite being1083
rather different. Therefore, we avoid this term in this review. The second type of1084
approach is difficult in terms of delivery. In the case of photon therapy, it could be1085
considered an extension of MLC tracking. We briefly review these works in section 6.4,1086
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however, we focus on the first type of approach that relates to robust planning more1087
directly.1088
6.1. Treatment plan optimization based on a known motion PDF1089
The ITV approach for moving tumors, and the PTV approach in general, aim to deliver1090
the prescribed dose to all regions were the tumor may be, regardless of how much time1091
the tumor spends in each position. In the presence of motion, and when the total tumor1092
dose is achieved by accumulating dose contributions from multiple geometric instances,1093
the ITV approach is suboptimal in terms of normal tissue sparing. In particular, normal1094
tissue dose can be reduced by delivering less dose to regions where the tumor is rarely.1095
To ensure that this dose reduction does not compromise target coverage, higher doses1096
should be delivered to regions largely occupied by the tumor.1097
To formalize this concept, assume that a lung tumor accumulates dose over different1098
phases ϕ of the breathing cycle, and let wϕ be the nonnegative fraction of time spent in1099
each phase. Each phase has an associated dose-influence matrix Dϕ, whose calculation1100
usually involves deformable image registration to map voxels in each breathing phase to1101
their location in a reference phase. Let us assume that the total dose accumulated over1102
a breathing cycle can be approximated as1103
d =
∑
ϕ
wϕDϕx = D¯x ,
∑
ϕ
wϕ = 1 (27)1104
where1105
D¯ =
∑
ϕ
wϕDϕ (28)1106
is an effective dose-influence matrix. It is important to note that wϕ is not a scenario1107
probability but the fraction of time spent in phase ϕ. Further, it is important to dis-1108
tinguish motion from uncertainty. Up to this point, no uncertainty is considered, i.e.1109
it is assumed that the cumulative dose is given by blurring a nominal dose distribution1110
with the known motion PDF. This is similar to the handling of random errors discussed1111
in section 4 for an infinite number of fractions. Using a fixed effective dose-influence1112
matrix D¯ in IMRT optimization will create a treatment plan featuring horns, which is1113
optimal for the assumed motion pattern characterized by wϕ.1114
1115
This approach was studied by various authors. So¨hn et al [104] used the probabil-1116
ity density function (wϕ) to explicitly optimize the accumulated dose under respiratory1117
motion for lung patients and showed that their plan generated similar results as gat-1118
ing. Zhang et al [105] concluded that the approach can achieve plans similar to those1119
achieved by real-time target tracking. Watkins et al [106] and Lens et al [107] compared1120
the motion PDF approach and ITV planning, and showed that it resulted in similar1121
target coverage but significantly lower dose to surrounding healthy tissues. In the study1122
by Watkins et al [106], target coverage and OAR sparing was mostly maintained when1123
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the motion PDF differed from that assumed during optimization. The motion PDF ap-1124
proach was also studied in IMPT in combination with the voxel-wise worst-case method1125
for handling range and setup uncertainty [97].1126
1127
6.2. Robust planning for handling uncertainty in the motion PDF1128
A treatment that is optimized for a fixed motion PDF may degrade if the actual breath-1129
ing pattern varies substantially from the assumed motion PDF wϕ. Robust planning1130
methods can be used to robustify the plan against uncertainty in the breathing pattern.1131
One approach to parameterize this uncertainty is to assume uncertainty in wϕ, i.e. un-1132
certainty in the amount of time spent in each phase. This can be done by defining a set1133
of possible breathing patterns wϕk , which translates into a set of effective dose-influence1134
matrices D¯k. Subsequently, any of the robust planning concepts described in section 3.31135
such as the minimax or stochastic programming approach can be applied. However, in1136
this case it is also possible to consider a continuous uncertainty set W , containing a set1137
of realistic breathing PDFs.1138
1139
This robust planning approach is a generalization of both the ITV approaches1140
and optimization based on a fixed PDF. The fixed PDF approach can be recovered by1141
simply setting the uncertainty set W to be a single vector equal to wϕ for all ϕ. At1142
the other end of the spectrum, the largest set that W could be is the unit simplex:1143
{wϕ : ∑ϕwϕ = 1, wϕ ≥ 0,∀ϕ}. This set models the situation where the breathing1144
motion can be any possible breathing pattern, including ones where the patient spends1145
100% of the time at a single phase in the breathing cycle. This is representative of the1146
ITV approach. An intermediate choice ofW results in a solution that balances between1147
healthy tissue sparing and target coverage under breathing motion uncertainty. Thus,1148
the robust optimization approach generates a continuum of robustness that allows the1149
decision maker to modulate the degree of conservatism when designing the treatment1150
[108].1151
1152
Several robust planning approaches for handling respiratory motion including un-1153
certainty in breathing patterns have been investigated [17, 109, 8]. Unkelbach et al1154
[109] investigated a stochastic programming approach for handling uncertain respiratory1155
motion. The work first considered uncertainty in the motion PDF as well as breathing1156
amplitude and baseline variations in a 1-dimensional phantom. This work was expanded1157
by Heath et al [8] and demonstrated for a lung cancer patient. The latter work also1158
provides a comparison of stochastic programming to the voxel-wise worst case method1159
described in section 3.4.3. Chan et al [17] were the first to propose a robust optimiza-1160
tion approach, which was demonstrated in a simplified 1-dimensional phantom. Later,1161
this approach was generalized and demonstrated in a lung patient geometry, with the1162
formal mathematical development of the continuum of robustness defined above [108].1163
Robust radiotherapy planning 36
This approach was then adapted to optimize the DVH tails in breast IMRT under res-1164
piratory motion uncertainty, where the key trade-off was between cardiac sparing and1165
target coverage [110]. This approach demonstrated the potential to reduce the need1166
for breath-hold techniques [111], without requiring much extra computational effort to1167
solve the more challenging, tail DVH-based robust optimization problem [112].1168
1169
One of the consistent findings from robust treatment planning approaches is the1170
presence of horns in the dose distribution that would be delivered to a static geometry,1171
which are designed such that edge-enhancements are washed out by the motion so that1172
the prescribed cumulative dose is delivered to the target volume. For robust planning1173
approaches, the horns are smoother and less pronounced compared to treatment plan-1174
ning based on a fixed breathing PDF. In fact, depending on the degree of uncertainty in1175
the breathing PDF, the approach can interpolate between an ITV-like treatment plan1176
and the fixed PDF situation.1177
1178
In contrast to the case of random errors for setup and inter-fraction motion, horns1179
may be an acceptable approach to handle motion in the case of breathing motion. In1180
fact, in lung or liver SBRT highly non-uniform dose distributions are delivered in clinical1181
practice, which show hot spots of up to 150% of the prescription dose inside the target1182
volume. Although, these treatment plan may be motivated by other considerations, this1183
also facilitates target coverage with smaller margins. This aspect has been investigated1184
theoretically by Chan et al [113, 114], showing that horns can be optimal in dealing with1185
motion. Vranvcic et al [115] provided experimental validation by delivering horn-based1186
fluence maps on a linear accelerator. McCann et al [116] and Ahanj et al [117] showed1187
that edge-enhanced intensity maps at inhale and smaller beam apertures during inhale1188
can provide the same coverage as margins but potentially reduce the dose to healthy1189
tissue for lung cancer.1190
6.3. Combining adaptation with robust optimization1191
Adaptive radiation therapy describes a broad paradigm of closed-loop decision making1192
where parameters are updated as a treatment progresses to improve the quality of1193
the final treatment [118]. Although not originally proposed for dealing with uncertain1194
respiratory motion, the concept was adapted to this case to further improve the1195
performance of previously proposed robust optimization models, which are limited by a1196
fundamental trade-off: a larger uncertainty set results in better target coverage at the1197
expense of increased normal tissue dose. To push this trade-off frontier forward, Chan et1198
al [119] proposed an adaptive robust optimization approach where the uncertainty set is1199
updated from fraction to fraction based on past observations of the patient’s breathing1200
pattern. They showed that simultaneous improvements in both target coverage and1201
normal tissue sparing were possible, and provided theoretical justification to support the1202
effectiveness of their approach. Subsequent research showed that the adaptive robust1203
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approach also performed well when considering daily dose metrics [120] and breathing1204
patterns that drifted over time [121].1205
6.4. Plan optimization assuming synchronization of tumor motion and delivery1206
Another approach to incorporate respiratory motion in treatment plan optimization1207
consist in optimizing a separate fluence map for every respiratory phase. In this case,1208
the cumulative dose distribution1209
d =
∑
ϕ
Dϕxϕ (29)1210
is given by the sum of doses Dϕxϕ delivered in each phase, where xϕ is the fluence1211
map delivered while the patient is in phase ϕ. The objective function is evaluated for1212
the cumulative dose and minimized with respect to all fluence maps simultaneously.1213
In principle, this approach can provide a treatment that improves even on the current1214
approach to MLC or couch tracking. In the current approach to tracking, a treatment1215
plan is optimized for one respiratory phase. During delivery using MLC tracking, the1216
apertures of the treatment plan are shifted to compensate for target translation. The1217
above approach can in principle improve on that. A treatment that allows for distinct1218
fluence maps for each resiratory phase can treat different parts of the target volume1219
primarily in the respiratory phase that is the most suited, e.g. when the target moves1220
away from an OAR during inhale or exhale. In other words, this approach does not only1221
mitigate motion, but may exploit motion to improve a plan over the static situation.1222
1223
This approach has been investigated by Trofimov et al [122] and compared to other1224
motion handling approaches. Nohadani et al [123] added constraints on the fluence1225
maps to the treatment plan optimization problem to enforce similarity of fluence maps1226
for neighboring respiratory phases. In these works, the approach of delivering sepa-1227
rate fluence maps for each respiratory phase was investgated conceptually, however, the1228
question how such treatment plans would be delivered efficiently was not addressed.1229
1230
Obtaining a deliverable treatment plan requires an optimization method that is1231
aware of the delivery process. In photon therapy, this is the case for direct aperture1232
optimization. Assuming that both the motion of the tumor and the delivery of a1233
treatment plan over time is known a priori, each aperture can be assigned to a particular1234
breathing phase. In this case, a set of apertures is optimized based on their cumulative1235
dose, assuming that each aperture is delivered during a known breathing phase. Such1236
an approach was investigated for VMAT and for IMRT planning by several groups1237
[124, 125, 126]. Similarly, in proton therapy a predetermined scan path can be considered1238
such that each pencil beam spot can be assigned to a given breathing phase during plan1239
optimization. The cumulative dose to a voxel i can then be written as1240
di =
∑
ϕ
∑
j
zjϕD
ϕ
ijxj (30)1241
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where zjϕ is a binary indicator that assigns pencil beam j to phase ϕ, i.e. zjϕ = 1 if1242
pencil beam j is delivered during phase ϕ and zero otherwise. Such an approach was1243
investigated by Bernatowicz et al [127] and others. In this approach, a single fluence1244
map is optimized, but different beamlets are assigned to different phases. The resulting1245
treatment plan can therefore not reach the theoretical optimum where a separate fluence1246
map per phase is optimized, however, the approach would substantially improve on any1247
margin approach. The review by Bert et al [128] presents a detailed review of respiratory1248
motion management in proton therapy. So far, these approaches have assumed a1249
perfect synchronization of tumor motion and treatment delivery and did not consider1250
uncertainty in the delivered dose. In that sense, they represent a method to incorporate1251
respiratory motion in treatment planning, but not a robust planning method to account1252
for uncertainty in planning and delivery. Engwall et al. [129] applied robust optimization1253
to account for uncertainties in breathing motion and delivery synchronization while1254
optimizing a single proton spot scanning pattern to be delivered over the different phases.1255
The consideration of multiple breathing motion scenarios resulted in reduced sensitivity1256
to the interplay effect due to irregularities in the breathing motion for the considered1257
patients.1258
7. Discussion1259
The fundamental limitations of the PTV concept in IMPT led to the first implemen-1260
tations of robust planning in commercial treatment planning systems. Thereby, robust1261
planning has evolved from a research topic to a methodology used in clinical prac-1262
tice of proton therapy planning. RayStation (RaySearch Laboratories) supports robust1263
optimization for photons, protons, and carbon ions based on the composite worst-case1264
approach (equation 6). Robust optimization for protons is also available in Eclipse (Var-1265
ian), which features an implementation of the voxelwise worst-case approach (equation1266
11) similar as described by Liu et al [89], and in Pinnacle (Philips Healthcare), which1267
follows the probabilistic approach (equation 5) [130].1268
1269
All three of the commercial implementations can take patient setup uncertainty1270
and particle range uncertainty into consideration. The magnitude of the setup shifts to1271
be accounted for is generally specified separately for left-right, anterior-posterior, and1272
superior-inferior direction; the magnitude of particle range errors to be accounted for is1273
specified in percent of the nominal range. RayStation can also handle organ motion by1274
using multiple existing patient images, such as the phases of a 4D-CT, or by generating1275
synthetic images that simulate organ motion. Robust optimization in RayStation was1276
the first commercial implementation and has been evaluated for protons in several works1277
[60, 61, 62, 63, 64, 65, 66, 67]. Similar studies were done for Eclipse [131, 132, 59]1278
1279
The limitations of the PTV approach are less severe in IMRT compared to IMPT,1280
and robust planning for systematic errors based on quadratic penalty functions yields1281
Robust radiotherapy planning 39
treatment plans that are often qualitatively similar to PTV based treatment plans. Situ-1282
ations where robust planning would have a fundamental advantage such as TCP/NTCP1283
based optimization or dose painting [16], are not commonly done in practice so far.1284
Perhaps therefore, the application of robust planning for IMRT has lagged behind that1285
for IMPT, even though methods like stochastic programming were initially investigated1286
for geometric uncertainty in IMRT and were only later applied to IMPT. Raystation is1287
the only commercial planning system that supports the use of robust optimization for1288
IMRT planning, which has been evaluated in a number of publications in recent years1289
[133] including applications to breast [134, 135], lung [136, 137], and glioblastoma [138].1290
1291
Even though IMRT planning systems do not commonly support robust optimization1292
methods, for some applications, it is possible to mimick the nature of the robust solution,1293
obtained from a research TPS, with a commercial one. For the case of boosting lymph1294
nodes of cervix patients in a simultaneous integrated boost technique, the coverage1295
probability approach by Baum [49] (section 4.6) was established and clinically validated1296
[139, 140] by a transfer of dose plan features obtained from the experimental TPS1297
Hyperion to Varian Eclipse RapidArc plans. The positive experience with this technique1298
have led to planning goals for the EMBRACE II cervix cancer trial that derive from1299
robust planning concepts, and not PTV concepts [141].1300
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